FYARRO

Serial Number 88599810
606

Registration Progress

Application Filed
Aug 30, 2019
Under Examination
Sep 22, 2020
Approved for Publication
Jul 28, 2020
Published for Opposition
Jul 28, 2020
Registered

Trademark Image

FYARRO

Basic Information

Serial Number
88599810
Filing Date
August 30, 2019
Published for Opposition
July 28, 2020
Abandonment Date
October 23, 2023
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 23, 2023
Classes
005 042

Rights Holder

AADi Bioscience, Inc.

03
Address
17383 Sunset Blvd., Suite A250
Pacific Palisades, CA 90272

Ownership History

AADi Bioscience, Inc.

Original Applicant
03
Pacific Palisades, CA

AADi Bioscience, Inc.

Owner at Publication
03
Pacific Palisades, CA

Legal Representation

Attorney
Aaron D. Hendelman

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

44 events
Date Code Type Description Documents
Oct 23, 2023 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Oct 23, 2023 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Mar 22, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 21, 2023 EX5G S SOU EXTENSION 5 GRANTED Loading...
Mar 17, 2023 EXT5 S SOU EXTENSION 5 FILED Loading...
Mar 17, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 23, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 21, 2022 EXT4 S SOU EXTENSION 4 FILED Loading...
Sep 21, 2022 EX4G S SOU EXTENSION 4 GRANTED Loading...
Sep 21, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 7, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 7, 2022 NOAC E CORRECTED NOA E-MAILED Loading...
May 6, 2022 EX3G S SOU EXTENSION 3 GRANTED Loading...
May 6, 2022 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
Apr 11, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 5, 2022 INCD O ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST Loading...
Apr 1, 2022 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Mar 22, 2022 EXT3 S SOU EXTENSION 3 FILED Loading...
Mar 21, 2022 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
Mar 21, 2022 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Mar 21, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 22, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 20, 2021 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 20, 2021 EXT2 S SOU EXTENSION 2 FILED Loading...
Sep 20, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 25, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 23, 2021 EX1G S SOU EXTENSION 1 GRANTED Loading...
Feb 23, 2021 EXT1 S SOU EXTENSION 1 FILED Loading...
Feb 23, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 22, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 28, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jul 28, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 8, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 24, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jun 24, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 24, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 16, 2020 ALIE A ASSIGNED TO LIE Loading...
Jun 8, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Dec 11, 2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Dec 11, 2019 GNRT F NON-FINAL ACTION E-MAILED Loading...
Dec 11, 2019 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 4, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 12, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 3, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, epilepsy, mitochondrial disease, central nervous system disease, infectious disease, and acute respiratory disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in in pediatric, geriatric, emergency, family, and psychiatry; pharmaceutical preparations for the treatment of infectious and hereditary diseases
Class 042
Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases

Classification

International Classes
005 042